5
Checkpoint Trends Ltd
RUBRAMEDICAMENTSLTD NSE
Checkpoint Trends Ltd
HealthcareNSE: RUBRAMEDICAMENTSLTD BSE: 531099 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹22.75 Cr
Volatility
Moderate
P/E Ratio
10.6
EBITDA
₹0.10 Cr
Return on Equity
-15.63%
Debt to Equity
0
Book Value
₹3.6
EPS
₹0.06
52W High
₹144.4
52W Low
₹16.06
Technical Indicators
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
5- Stock is trading at 11.0 times its book value
- The company has delivered a poor sales growth of -12.8% over past five years.
- Company has a low return on equity of 0.00% over last 3 years.
- Company has high debtors of 212 days.
- Working capital days have increased from 220 days to 387 days
Growth Rate
Revenue Growth
-54.55% ↘
Net Income Growth
810.00% ↗
Cash Flow Change
0.19% ↗
ROE
-19.75% ↘
ROCE
102.36% ↗
EBITDA Margin (Avg.)
324.05% ↗
Quarterly Results
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS in Rs | 0 | -0.18 | -0.09 | 0.48 | 0.11 | -0.42 | 0.04 | -0.07 | -0.04 | 0.11 | 0.16 | 2.41 | 1.04 |
| Expenses | 0.21 | 0.19 | 0.25 | 0.03 | 0.11 | 0.71 | 0.07 | 0.08 | 0.14 | 0.16 | 11.62 | 107 | 173 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | -0.1 | -0.05 | 0.26 | 0.06 | -0.23 | 0.02 | -0.04 | -0.02 | 0.06 | 0.09 | 1.32 | 0.57 |
| OPM % | 0% | -137.5% | -25% | 89.66% | 35.29% | -51.06% | 30% | -60% | -40% | 36% | 0.77% | 1.66% | 0.44% |
| Operating Profit | 0 | -0.11 | -0.05 | 0.26 | 0.06 | -0.24 | 0.03 | -0.03 | -0.04 | 0.09 | 0.09 | 1.8 | 0.77 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | -0.02 | 0 | 0 | 0 |
| PBT | 0 | -0.11 | -0.05 | 0.26 | 0.06 | -0.24 | 0.03 | -0.03 | -0.02 | 0.07 | 0.09 | 1.8 | 0.77 |
| Sales | 0.21 | 0.08 | 0.2 | 0.29 | 0.17 | 0.47 | 0.1 | 0.05 | 0.1 | 0.25 | 11.71 | 109 | 174 |
| Tax % | — | -9.09% | 0% | 0% | 0% | -4.17% | 0% | 33.33% | 0% | 0% | 0% | 26.11% | 25.97% |
Profit & Loss
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| EPS in Rs | -0.11 | -5.61 | -0.02 | 0.05 | -0.29 | -0.02 | 0.05 | 0.02 | -0.07 | -0.15 | 0.05 | 0.05 | 3.72 |
| Expenses | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 292 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| OPM % | — | — | -5% | 10% | -1% | -31% | 2% | 2% | -1% | -7% | 3% | 20% | 1% |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Other Income | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Sales | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 295 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 20% | 0% | 50% | 0% | -50% | 40% | — |
Balance Sheet
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 141 |
| Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 139 |
| Reserves | -2 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -4 |
| Total Assets | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 141 |
| Total Liabilities | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 141 |
Cash Flow
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CFO/OP | 83 | 114 | 100 | 133 | -600 | 17 | 650 | 5,200 | 2,450 | -12 | 0 | 190 |
| Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Ratios
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Conversion Cycle | — | — | 36 | 24 | 54 | 179 | 107 | 164 | 122 | 135 | 229 | 212 |
| Debtor Days | — | — | 36 | 24 | 54 | 179 | 107 | 164 | 122 | 135 | 229 | 212 |
| Inventory Days | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| ROCE % | -2% | -3% | -3% | 7% | 25% | -31% | 3% | 2% | -3% | -13% | 3% | 17% |
| Working Capital Days | — | — | 18 | -35 | 36 | 260 | 221 | 60 | 98 | 129 | 145 | 387 |
Documents
Outcome Of The Board Meeting
2025-08-06
Outcome Of Board Meeting
2024-08-13
Outcome Of Board Meeting
2024-02-07
Outcome Of Board Meeting
2023-11-07
Outcome Of Board Meeting
2023-05-26
Revised Outcome Of Board Meeting
2022-11-14
Outcome Of Board Meeting
2022-11-10
Outcome Of Board Meeting
2022-05-25
Outcome Of Board Meeting
2021-06-29
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
29 Apr - Company confirms it is not a Large Corporate Entity; FY2025-26 debt borrowing was 6.73 crore.
29 Apr - Company confirms it is not a Large Corporate Entity; FY2025-26 debt borrowing was 6.73 crore.
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
29 Apr - Centuple Global confirms it is not a large corporate; borrowings stood at ₹6.73 crore on March 31, 2026.
29 Apr - Centuple Global confirms it is not a large corporate; borrowings stood at ₹6.73 crore on March 31, 2026.
Clarification On Price Movement Of Equity Shares
24 Apr - April 24, 2026: Company said share price movement is market-driven, with no undisclosed announcements.
24 Apr - April 24, 2026: Company said share price movement is market-driven, with no undisclosed announcements.
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
29 Apr - Company confirms it is not a Large Corporate Entity; FY2025-26 debt borrowing was 6.73 crore.
29 Apr - Company confirms it is not a Large Corporate Entity; FY2025-26 debt borrowing was 6.73 crore.
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
29 Apr - Centuple Global confirms it is not a large corporate; borrowings stood at ₹6.73 crore on March 31, 2026.
29 Apr - Centuple Global confirms it is not a large corporate; borrowings stood at ₹6.73 crore on March 31, 2026.
Clarification On Price Movement Of Equity Shares
16h - April 24, 2026: Company said share price movement is market-driven, with no undisclosed announcements.
16h - April 24, 2026: Company said share price movement is market-driven, with no undisclosed announcements.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Regulation 74(5) confirmation certificate filed for quarter ended March 31, 2026.
9 Apr - Regulation 74(5) confirmation certificate filed for quarter ended March 31, 2026.
Clarification Sought from Checkpoint Trends Ltd
15 Apr - Exchange has sought clarification from Checkpoint Trends Ltd on April 15, 2026 with reference to significant movement in price, in order to ensure that investors …
15 Apr - Exchange has sought clarification from Checkpoint Trends Ltd on April 15, 2026 with reference to significant movement in price, in order to ensure that investors …
Closure of Trading Window
24 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for year ending March 31, 2026.
24 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for year ending March 31, 2026.
Board Meeting Outcome for Outcome Of Board Meeting
18 Mar - Two independent directors resigned; two additional independent directors appointed effective March 18, 2026.
18 Mar - Two independent directors resigned; two additional independent directors appointed effective March 18, 2026.
Board Meeting Intimation for The Meeting Of Board Of The Company Is Scheduled To Be Held On Wednesday, March 18, 2026
10 Mar - Board meeting on March 18, 2026 to consider resignation and appointment of independent director; trading window closed from March 10.
10 Mar - Board meeting on March 18, 2026 to consider resignation and appointment of independent director; trading window closed from March 10.
Announcement under Regulation 30 (LODR)-Allotment
5 Mar - Allotment of 1,66,74,072 warrants at ₹45.01 each, raising ₹75.05 crore; 25% received.
5 Mar - Allotment of 1,66,74,072 warrants at ₹45.01 each, raising ₹75.05 crore; 25% received.
Board Meeting Outcome for Subject: Outcome Of The Board Meeting For Allotment Of 1,66,74,072 (One Crores Sixty Six Lakhs Seventy Four Thousand Seventy Two) Convertible Warrants ('Warrants').
5 Mar - Allotted 1,66,74,072 warrants at Rs45.01 each, raising Rs75.05 crore, March 5, 2026.
5 Mar - Allotted 1,66,74,072 warrants at Rs45.01 each, raising Rs75.05 crore, March 5, 2026.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2 Mar - Hindustan Unilever to meet ICICI Group investors physically on 6 March 2026.
2 Mar - Hindustan Unilever to meet ICICI Group investors physically on 6 March 2026.
Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
15h - HUL completed sale of its entire 19.8% stake in Nutritionalab for approx INR 307 Crore on 4 March 2026.
15h - HUL completed sale of its entire 19.8% stake in Nutritionalab for approx INR 307 Crore on 4 March 2026.
Cancellation Of Board Meeting
25 Feb - Board meeting scheduled February 25, 2026 cancelled; company to inform revised date if any.
25 Feb - Board meeting scheduled February 25, 2026 cancelled; company to inform revised date if any.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
20 Feb - Kotak 'Chasing Growth' investor meet on 25 Feb 2026, physical conference.
20 Feb - Kotak 'Chasing Growth' investor meet on 25 Feb 2026, physical conference.
Board Meeting Intimation for Intimation Of Board Meeting For The Meeting To Be Held On February 25, 2026
20 Feb - Board meeting Feb 25, 2026: WTD resignation, new WTD appointment, acquisition proposal, related-party transaction; trading window closed.
20 Feb - Board meeting Feb 25, 2026: WTD resignation, new WTD appointment, acquisition proposal, related-party transaction; trading window closed.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
19 Feb - Transcript of the Earnings Conference Call for the quarter ended 31st December, 2025
19 Feb - Transcript of the Earnings Conference Call for the quarter ended 31st December, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On 18Th February 2026
18 Feb - HUL to invest up to ₹2,000 crore over two years to expand premium category manufacturing.
18 Feb - HUL to invest up to ₹2,000 crore over two years to expand premium category manufacturing.
Material Update In Connection With The Scheme Of Arrangement - Communication Received From Kwality Wall''s (India) Limited
13 Feb - KWIL 2,34,95,91,262 shares (Re.1) approved for listing; trading starts 16-Feb-2026.
13 Feb - KWIL 2,34,95,91,262 shares (Re.1) approved for listing; trading starts 16-Feb-2026.
Announcement under Regulation 30 (LODR)-Updates on Acquisition
13 Feb - HUL completed acquisition of remaining 49% of Zywie for INR 824 Crore on Feb 13, 2026.
13 Feb - HUL completed acquisition of remaining 49% of Zywie for INR 824 Crore on Feb 13, 2026.
Concall - Jan 2016
Jan 2016
Concall - Jul 2016
Jul 2016
Concall - Oct 2016
Oct 2016
Concall - Nov 2016
Nov 2016
Frequently Asked Questions about Checkpoint Trends Ltd
What does Checkpoint Trends Ltd do?
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]
Where is Checkpoint Trends Ltd (531099) listed?
Checkpoint Trends Ltd is listed on the Indian stock exchanges. It is listed on NSE: RUBRAMEDICAMENTSLTD and BSE: 531099. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Checkpoint Trends Ltd belong to?
Checkpoint Trends Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Checkpoint Trends Ltd?
Checkpoint Trends Ltd has a market capitalisation of approximately ₹22.75 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Checkpoint Trends Ltd?
The Price-to-Earnings (PE) ratio of Checkpoint Trends Ltd is 10.60. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Checkpoint Trends Ltd?
Over the past 52 weeks, Checkpoint Trends Ltd has traded between a low of ₹16.06 and a high of ₹144.4. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Checkpoint Trends Ltd?
Checkpoint Trends Ltd has a Return on Equity (ROE) of -15.63%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Checkpoint Trends Ltd on Tapetide?
On Tapetide, you can view Checkpoint Trends Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]
Website rubramed.com
Face Value ₹ 10